Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | GLS | O94925 | 3/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896757 | 1.00 | BRD4 (0.48) | BRD4L3MBTL1GRM2NAMPTGLS | |
| SCHEMBL30399922 | 0.84 | L3MBTL1 (0.49) | BRD4L3MBTL1GRM2NAMPTGLS | |
| SCHEMBL15871964 | 0.84 | BRD4 (0.49) | BRD4L3MBTL1GRM2NAMPTGLS | |
| SCHEMBL10163771 | 0.84 | L3MBTL1 (0.49) | BRD4L3MBTL1GRM2NAMPTGLS | |
| SCHEMBL8247006 | 0.84 | LOXL2 (0.47) | BRD4L3MBTL1GRM2NAMPTGLS | |
| SCHEMBL337888 | 0.83 | L3MBTL1 (0.48) | BRD4L3MBTL1GRM2NAMPTGLS | |
| SCHEMBL14200095 | 0.83 | LMNA (0.52) | BRD4L3MBTL1GRM2NAMPTGLS | |
| SCHEMBL30392761 | 0.83 | L3MBTL1 (0.48) | BRD4L3MBTL1GRM2NAMPTGLS | |
| SCHEMBL13391259 | 0.83 | L3MBTL1 (0.48) | BRD4L3MBTL1GRM2NAMPTGLS | |
| SCHEMBL14228526 | 0.83 | BRD4 (0.48) | BRD4L3MBTL1GRM2NAMPTGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4028131-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | BRD4 20/4885L3MBTL1 2105/4885GRM2 2796/4885 |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | BRD4 20/4885L3MBTL1 2105/4885GRM2 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.